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Objective: Recent studies have suggested that statins reduce atrial fibrillation after
cardiothoracic surgery, but the use of proven prophylactic strategies such as beta-
blockers and amiodarone in these studies was not provided. Therefore, we sought
to determine whether preoperative statin use could reduce the incidence of post-
cardiothoracic surgery atrial fibrillation in a population who already had a high back-
ground use of beta-blockers and appreciable use of prophylactic amiodarone.
Methods: Patients undergoing cardiothoracic surgery from the randomized, con-
trolled Atrial Fibrillation Suppression Trials I, II, and III were evaluated in this nested
cohort evaluation. The patients’ demographics, surgical characteristics, medication
use, and incidence of post-cardiothoracic surgery atrial fibrillation (atrial fibrillation
.5 minutes duration) were uniformly and prospectively collected as part of Atrial Fi-
brillation Suppression Trials I, II, and III. Multivariate logistic regression was used to
calculate adjusted odds ratios with 95% confidence intervals.
Results: Overall, 331 patients (59.6%) received a statin preoperatively and 224
patients (40.4%) did not. The study population had an average age of 67.8 6 8.6
years, 77.1% were male, 14.6% had valve surgery, 6.1% had a history of atrial
fibrillation, 12.6% had a history of heart failure, 84.0% received postoperative
beta-blockade, and 44.1% received postoperative prophylactic amiodarone. In total,
174 patients (31.4%) developed post-cardiothoracic surgery atrial fibrillation. Upon
multivariate logistic regression, statin use was associated with a reduction in post-
cardiothoracic surgery atrial fibrillation (adjusted odds ratio: 0.60; 95% confidence
interval 0.37–0.99). Higher intensity statin dosing (equivalent of $40 mg of ator-
vastatin) seemed to be associated with the greatest reductions in post-cardiothoracic
surgery atrial fibrillation (adjusted odds ratio: 0.45; 95% confidence interval 0.21–
0.99).
Conclusions: In a population with appreciable beta-blocker and amiodarone use, ad-
junctive preoperative statin use was still associated with a 40% reduction in patients’
odds of developing post-cardiothoracic surgery atrial fibrillation.
A
pproximately 666,000 cardiothoracic surgeries (CTS) were performed in the
United States in 2003.1 One of the most common complications after CTS is
the development of atrial fibrillation (AF). Although typically self limiting,
post-CTS AF can increase a patient’s risk for hemodynamic instability and stroke.2
Moreover, it prolongs the length of stay and increases total hospital costs.2,3 Beta-
blockers and amiodarone are thus commonly used to prevent post-CTS AF and
have been effective according to a recent meta-analysis.4 Even with prophylactic
beta-blockade and/or amiodarone, up to 40% of patients still develop post-CTS
AF.4-7
Given the antiadrenergic effects of beta-blockers and amiodarone, the risks of hy-
potension, bradycardia, and heart block are elevated. Additional adjunctive strategies
to further impede sympathetic functioning will likely exacerbate these adverse events;
therefore, a novel strategy for reducing post-CTS AF is required.
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Inflammation may be a causative factor in the develop-
ment of postoperative and nonsurgical AF.8-11 Given the
ability of statins to attenuate inflammation,12-14 previous
studies have assessed the relationship between statin use
pre-CTS and the subsequent development of AF after sur-
gery.15-18 Unfortunately, none of these studies assessed
statin efficacy when added to appreciable prophylaxis with
beta-blockers and amiodarone. Whether statins would still
maintain efficacy when added to a population receiving
higher levels of prophylactic beta-blockers and amiodarone
is not known.
By combining the patient data from 3 randomized and
controlled clinical trials, the Atrial Fibrillation Suppression
Trials (AFIST) I, II, and III,6,7,19 we had 555 patients who
had undergone CTS fromwhom to conduct a ‘‘nested’’ study.
All of the data were prospectively determined during the
trials, end point definitions were the same, postoperative
beta-blocker administration was high, and use of prophylac-
tic amiodarone was substantial. We therefore examined the
impact of preoperative statin use on the incidence of post-
operative AF in this nested population.
Materials and Methods
Design and Population
Our study prospectively evaluated a nested cohort of 555 patients
who underwent coronary artery bypass grafting and/or valvular sur-
gery as part of the AFIST I, II, and III. This study was approved by
the Hartford Hospital Institutional Review Committee after expe-
dited review.
AFIST I6 was a randomized, double-blind, placebo-controlled
trial that assessed the effect of oral amiodarone or placebo on the in-
cidence of AF after cardiac surgery (n5 217). Patients enrolled less
than 5 days before surgery received 6 g of amiodarone or placebo
during 6 days beginning on preoperative day 1. Patients enrolled
at least 5 days before surgery received 7 g during 10 days beginning
on preoperative day 5. AFIST II7 was a 2 3 2 factorial study that
assessed the effect of 2 active treatments (amiodarone and atrial sep-
tal pacing) on the incidence of AF after cardiac surgery (n 5 160).
Patients were initially randomized to either amiodarone or placebo
and then randomized further to either atrial septal pacing or no pac-
ing. AFIST III19 was a randomized controlled trial that assessed the
effect of aortic fat pad maintenance on the incidence of postopera-
tive AF in patients (n 5 178) undergoing coronary artery bypass
graft surgery for the first time.
Data with respect to patient demographics, surgical characteris-
tics, medication use, and postoperative AF were prospectively and
uniformly collected as part of AFIST I, II, and III. In AFIST I, II,
and III, the primary end point was the development of post-CTS406 The Journal of Thoracic and Cardiovascular Surgery c FebrAF within 30 days of cardiac surgery. AF was defined as episodes
lasting more than 5minutes as documented by continuous telemetry.
Statin use and dose were recorded. The statins were converted to
atorvastatin equivalents using the following conversions: atorvasta-
tin 10 mg5 simvastatin 5–20 mg, lovastatin 10–40 mg, pravastatin
10–40 mg, fluvastatin 20–80 mg, or cerivastatin 0.1–0.4 mg; ator-
vastatin 20mg5 simvastatin 40mg, pravastatin 80mg; rosuvastatin
5 mg, or cerivastatin 0.8 mg; atorvastatin 40 mg 5 simvastatin 80
mg or rosuvastatin 10 mg; atorvastatin 80 mg 5 rosuvastatin 20
mg.20-22
Statistical Analysis
Continuous variables are presented as means with standard devia-
tions and were compared between groups using a Student t test or
Mann–Whitney test when appropriate. Dichotomous variables are
presented as percentages and were compared between groups using
a chi-square or Fisher exact test when appropriate.
Because this was an observational study, the investigators had no
control over which patients received statins. As a result, significant
differences in observed demographic, surgical, and medication use
characteristics were expected. To control for these potential con-
founders and to avoid a biased estimate of treatment effect, we con-
ducted a multivariate logistic regression. Univariate analysis was
first performed to examine the relationship between different vari-
ables (demographic, surgical, and medication use characteristics)
and the development of postoperative AF (dependent variable).
All variables that showed a univariate association (P # .20) with
AF occurrence or that were previously demonstrated to be strong in-
dependent predictors ofAF3,6,7,19,23,24 were then entered into a back-
ward, stepwise multivariate regression model. Adjusted odds ratios
and 95% confidence intervals (CIs) were calculated for all indepen-
dent predictors. Statistical analysis was performed with the Statisti-
cal Package for the Social Sciences version 15.0 (SPSS Inc,
Chicago, Ill).
Results
A total of 555 patients were evaluated, of whom 331
(59.6%) received a statin preoperatively and 224 (40.4%)
did not. Overall, the study population had an average age
of 67.86 8.6 years, 77.1% were male, 14.6% had valve sur-
gery, 6.1% had a history of AF, 12.6% had a history of heart
failure, 84.0% received postoperative beta-blockade, and
44.1% received prophylactic amiodarone. Table 1 depicts
the results of univariate comparisons of demographic and
perioperative characteristics between patients receiving and
not receiving a statin. Similarly, comparisons of demograph-
ics and perioperative characteristics between patients devel-
oping and not developing post-CTS AF are provided in
Table 2.
In total, 174 patients (31.4%) developed AF after cardiac
surgery (36.6% vs 27.8% in the non-statin and statin groups,
respectively; crude odds ratio: 0.68; 95% CI: 0.46–0.96). Of
the 174 patients, only 1 developed AF after discharge but
within 30 days. On multivariate analysis (Table 3), the preop-
erative use of statins was associated with a statistically signif-
icant reduction in AF (adjusted odds ratio: 0.60; 95% CI:
0.37–0.99). Benefit was also seen with nonsteroidal,uary 2008
Lertsburapa et al Cardiopulmonary Support and Physiology
CS
PTABLE 1. Patient demographics, surgical characteristics, and medication use by statin use
No statin (n 5 224) Statin (n 5 331)
Variable n (%) n (%) P value
Preoperative characteristics
Age, y (mean 6 SD) 69.4 6 8.7 66.7 6 8.4 ,.001
Male gender 172 (76.8) 256 (77.3) .88
Participant in AFIST I 118 (52.8) 99 (29.9) ,.001
Participant in AFIST II 59 (26.3) 101 (30.5) .29
Participant in AFIST III 47 (21.0) 131 (39.6) ,.001
History of diabetes mellitus 64 (28.6) 120 (36.3) .06
History of hypertension 156 (69.6) 253 (76.4) .08
History of smoking 132 (58.9) 194 (58.6) .94
History of myocardial infarction 69 (30.8) 136 (41.1) .01
Family history of CAD 84 (37.5) 133 (40.2) .53
History of angina 158 (70.5) 250 (75.5) .19
History of heart failure 34 (15.2) 36 (10.9) .13
EF, % (mean 6 SD) 49.2 6 13.1 50.2 6 12.1 .46
.45 137 (61.6) 204 (61.6) .40
25-45 77 (34.4) 119 (36.0)
,25 10 (4.5) 8 (2.4)
Prior AF 13 (5.8) 21 (6.3) .79
History of cerebrovascular disease 11 (4.9) 16 (4.8) .97
History of COPD 33 (14.7) 43 (13.0) .56
History of mitral regurgitation 58 (25.9) 54 (16.3) .01
Vessels .50% occluded 2.6 6 1.1 2.9 6 0.8 .003
Preoperative medical therapy
Beta-blocker 145 (64.7) 264 (79.8) ,.001
CCB 48 (21.4) 49 (14.8) .04
Digoxin 12 (5.4) 16 (4.8) .78
ACEI or ARB 96 (42.9) 168 (50.8) .08
Surgical characteristics
Valve surgery 51 (22.8) 30 (9.1) ,.001
On-pump surgery 166 (74.1) 207 (62.5) .004
Duration of surgery, min, (mean 6 SD) 289.4 6 87.0 290.8 6 104.5 .87
No. of grafts, n, (mean 6 SD) 3.5 6 1.8 3.9 6 1.4 .005
No. of arterial Grafts, n, (mean 6 SD) 1.4 6 1.2 1.8 6 1.2 ,.001
No. of venous grafts, n, (mean 6 SD) 2.2 6 1.5 2.2 6 1.3 .81
Postoperative medication use
Amiodarone 101 (45.1) 144 (43.5) .71
Beta-blocker 180 (80.4) 286 (86.4) .06
CCB 17 (7.6) 37 (11.2) .16
Digoxin 73 (32.6) 74 (22.4) .007
Corticosteroids 77 (34.4) 71 (21.5) .001
NSAIDs 54 (24.1) 73 (22.1) .57
ACEI/ARB 86 (38.4) 132 (39.9) .73
Beta-blocker withdrawal 18 (8.0) 32 (9.7) .51
ACEI/ARB withdrawal 35 (15.6) 68 (20.5) .14
SD, Standard deviation; AFIST, Atrial Fibrillation Suppression Trial; CAD, coronary artery disease; EF, ejection fraction; COPD, chronic obstructive pulmonary
disease; CCB, calcium channel blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; NSAID, nonsteroidal anti-inflam-
matory drug.preoperative beta-blocker, and prophylactic amiodarone ad-
ministration (P# .04 for all). Age, number of arterial grafts,
beta-blocker withdrawal (patient treated with preoperative
beta-blocker but not receiving postoperative beta-blocker
before onset of AF), and histories of AF, diabetes mellitus,The Journal of Thand mitral valve regurgitation were positive risk factors for
developing AF after surgery (P # .04 for all).
When subgroup analysis evaluating the impact of differ-
ent statin dosing intensities was performed, statin doses
equivalent to $40 mg per day of atorvastatin resulted inoracic and Cardiovascular Surgery c Volume 135, Number 2 407
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CSPTABLE 2. Patient demographics, surgical characteristics, and medication use by postoperative cardiothoracic surgery
atrial fibrillation status
No post-CTS AF (n 5 381) Post-CTS AF (n 5 174)
Variable n (%) n (%) P value
Preoperative characteristics
Age, y (mean 6 SD) 66.7 6 8.5 70.2 6 8.4 ,.001
Male gender 301 (79.0) 127 (73.0) .12
Participant in AFIST I 153 (40.2) 64 (36.8) .45
Participant in AFIST II 111 (29.1) 49 (28.2) .81
Participant in AFIST III 117 (30.7) 61 (35.1) .31
History of diabetes mellitus 118 (31.0) 66 (37.9) .11
History of hypertension* 280 (73.5) 129 (74.1) .87
History of smoking* 228 (59.8) 98 (56.3) .43
History of myocardial infarction* 139 (36.5) 66 (37.9) .74
Family history of CAD 149 (39.1) 68 (39.1) ..99
History of angina 288 (75.6) 120 (69.0) .10
History of heart failure 37 (9.7) 33 (19.0) .002
EF, % (mean 6 SD)* 50.3 6 12.6 49.1 6 12.3 .31
.45 238 (62.5) 103 (59.2) .22
25-45 128 (33.6) 68 (39.1)
,25 15 (3.9) 3 (1.7)
Prior AF 15 (3.9) 19 (10.9) ,.001
History of cerebrovascular disease 17 (4.5) 10 (5.7) .51
History of COPD 45 (11.8) 31 (17.8) .06
History of mitral regurgitation 64 (16.8) 48 (27.6) .003
Vessels .50% occluded 2.8 6 0.9 2.6 6 1.1 .07
Preoperative medical therapy
Statin 142 (37.3) 82 (47.1) .04
Beta-blocker 291 (76.4) 118 (67.8) .03
CCB 63 (16.5) 34 (19.5) .39
Digoxin 16 (4.2) 12 (6.9) .18
ACEI/ARB 182 (47.8) 82 (31.1) .89
Surgical characteristics
Valve surgery 42 (11.0) 39 (22.4) ,.001
On-pump surgery* 258 (67.7) 115 (66.1) .71
Duration of surgery, min, (mean 6 SD) 283.9 6 81.9 304.1 6 124.8 .02
No. of grafts, n, (mean 6 SD) 3.8 6 1.5 3.7 6 1.7 .11
No. of arterial grafts, n, (mean 6 SD)* 1.6 6 1.2 1.6 6 1.2 .82
No. of venous grafts, n, (mean 6 SD) 2.2 6 1.4 2.1 6 1.4 .28
Postoperative medication use
Amiodarone 191 (50.1) 54 (31.0) ,.001
Beta-blocker 327 (85.8) 139 (79.9) .08
CCB 31 (8.1) 23 (13.2) .06
Digoxin 70 (18.4) 77 (44.3) ,.001
Corticosteroids* 100 (26.2) 48 (27.6) .74
NSAIDs 101 (26.5) 26 (14.9) .003
ACEI/ARB 147 (38.6) 71 (40.8) .62
Beta-blocker withdrawal 28 (7.3) 22 (12.6) .04
ACEI/ARB withdrawal 70 (18.4) 33 (19.0) .87
Statin withdrawal 54 (14.2) 20 (11.5) .39
CTS, Cardiothoracic surgery; AF, atrial fibrillation; SD, standard deviation; AFIST, Atrial Fibrillation Suppression Trial; CAD, coronary artery disease; EF, ejection
fraction; COPD, chronic obstructive pulmonary disease; CCB, calcium channel blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin
receptor blocker; NSAID, nonsteroidal, anti-inflammatory drug. *These independent variables were included in the multivariate analysis in addition to the
variables with a P # .20 because of previous evidence they are strong independent predictors of postoperative AF.408 The Journal of Thoracic and Cardiovascular Surgery c February 2008
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Variable
Total no. of
events/total AOR (95% CI) P value
Preoperative statin use 82/224 (36.6) 0.60 (0.37–0.99) .048
Prophylactic amiodarone use 54/245 (21.1) 0.36 (0.23–0.55) ,.001
Age (per 10 y) NA 1.60 (1.33–1.87) ,.001
History of AF 19/34 (55.9) 3.57 (1.60–7.80) .01
History of diabetes mellitus 66/184 (35.9) 1.70 (1.12–2.60) .01
History of mitral valve regurgitation 48/112 (39.3) 1.71 (1.04–2.83) .04
Preoperative beta-blocker use 139/409 (34.0) 0.61 (0.38–0.98) .04
No. of arterial grafts (per graft) NA 1.22 (1.02–1.47) .03
Postoperative nonsteroidal use 26/127 (20.5) 0.59 (0.35–0.99) .04
Beta-blocker withdrawal 22/50 (44.0) 2.17 (1.11–4.25) .02
AOR, Adjusted odds ratio; CI, confidence interval; AF, atrial fibrillation; NA, not available. *The Hosmer–Lemeshow goodness-of-fit test (c2 test statistic5 6.4;
degrees of freedom 5 8; P 5 .58); area under the receiver operator curve 5 0.7.the greatest reductions in post-CTSAF (55% reduction) com-
pared with those receiving$20 mg but less than 40 mg (43%
reduction) or less than 20 mg (25% reduction) (Figure 1). In
addition, patients receiving the equivalent of at least 20 mg of
atorvastatin (n 5 144) had a 40% reduction in the odds of
developing post-CTS AF (adjusted odds ratio: 0.60; 95%
CI: 0.23–0.99) versus patients receiving lower equivalent
doses of statin or no statin therapy (n5 411). When patients
receiving the equivalent of at least 20 mg of atorvastatin (n5
144) were compared with those receiving only low-intensity
statin therapy (n 5 187), there was a nonsignificant 29%
reduction in post-CTS AF (adjusted odds ratio: 0.71; 95%
CI: 0.41–1.25).
Discussion
To date, meta-analyses have demonstrated the efficacy of
only a few prophylactic strategies to reduce post-CTS AF:
beta-blockers, amiodarone, sotalol, magnesium, and biatrial
pacing.4,23 Although beta-blockers, amiodarone, and sotalolThe Journal of Thorare included in the most recent American College of Cardiol-
ogy/American Heart Association/European Society of Cardi-
ology practice guidelines for the management of post-CTS
AF, only amiodarone and beta-blockers have been shown
to be effective and safe when combined.24 However, the
use of these therapies can increase the risk of hypotension,
bradycardia, and heart block, making it unlikely that addi-
tional antiadrenergic drugs can be added to this combination
regimen.
Inflammation may be a causative factor in the develop-
ment of post-CTS AF. Bruins and colleagues9 documented
the presence of an inflammatory process by measuring levels
of interleukin-6 and C-reactive protein early in the postoper-
ative period. Their group demonstrated that these inflamma-
tory markers significantly increased after cardiac surgery,
with levels of C-reactive protein peaking around postopera-
tive day 2 and coinciding with the peak incidence of atrial
arrhythmias.9 The study was rather small, but these findings
were complemented by other reports that substantiated theCS
PFigure 1. Effect of statin dosing intensity on the
development of postoperative AF. AF, Atrial
fibrillation.acic and Cardiovascular Surgery c Volume 135, Number 2 409
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CSProle of inflammation in the development of both postopera-
tive and nonsurgical AF.8,10,11,18 Statins were subsequently
found to attenuate this inflammation. Kumagai and col-
leagues13 showed that atorvastatin was able to decrease
C-reactive protein levels while diminishing the AF burden
in a canine model of sterile pericarditis. Brull and col-
leagues25 noted decreased interleukin-6 levels in patients
who received statins before cardiac surgery.
Past observational studies have reported an association be-
tween preoperative statin use and reduced rates of post-CTS
AF.15-17 ARMYDA-3 was the first clinical trial to evaluate
the impact of statin therapy on post-CTS AF.18 Two hundred
patients undergoing elective CTS were randomized to either
atorvastatin (40 mg/d, n 5 101) or placebo (n 5 99) starting
7 days preoperatively. Post-CTS AF occurred in 35% of
patients in the atorvastatin arm and in 57% of patients in the
placebo arm, representing a 61% reduction (P5 .017) in AF
incidence in those who received statins. Before surgery,
beta-blockers were used by 72% and 60% of patients in the
atorvastatin and placebo arms, respectively, whereas amiodar-
one was administered to only 1 patient in each group. Similar
to the observational studies, no information was given regard-
ing the rates of postoperative beta-blocker and amiodarone
therapy; the 57% incidence of post-CTS AF in the placebo
group, however, suggests low use of these treatments.
In our study, patients from AFIST I, II, and III received
postoperative beta-blockers and amiodarone approximately
84.0% and 44.1% of the time, respectively. As expected,
the withdrawal of a beta-blocker postoperatively significantly
increased the incidence of AF, and the use of prophylactic
amiodarone significantly reduced the incidence of AF after
cardiac surgery. Multivariate analysis, however, also demon-
strated that statin use before surgery had a positive and inde-
pendent effect on AF rates. Specifically, patients taking
preoperative statins experienced a 40% reduction in their
odds of developing postoperative AF, an effect size compara-
ble to that seen in previous statin studies.16,17
Although our study was observational in nature, a num-
ber of characteristics helped limit the effects of confounding
and biases on our results. The use of ‘‘nested’’ data from the
previously conducted, prospective, randomized, and con-
trolled AFIST I, II, and III likely reduced the impact of selec-
tion, misclassification, surveillance, and researcher bias. Our
use of multivariate logistic regression to calculate adjusted
odds ratios likely minimized much of the confounding during
statistical analysis. Data on most of the commonly accepted
independent predictors of post-CTS AF identified in the
American College of Cardiology/American Heart Associa-
tion/European Society of Cardiology AF guidelines were
available for use in the multivariate adjustment. Yet even
with these measures, there is some degree of bias that cannot
be extracted during observational trials, representing a limita-
tion. It is also important to note that our multivariable analysis
may suffer from a mild degree of over-fitting.410 The Journal of Thoracic and Cardiovascular Surgery c FebOur study has other limitations that should be noted. First,
we converted all statins to an equivalent dose of atorvastatin;
although this was necessary to facilitate our high- versus low-
intensity comparison, it should be noted that antifibrillatory
effects might not be identical across all statins. Although
we were able to show that higher intensity statin therapy
was a negative independent predictor of post-CTS AF versus
the combined group receiving either no therapy or lower in-
tensity therapy, we did not have adequate power to evaluate
higher intensity versus lower intensity therapy by itself.
However, the adjusted odds of post-CTS AF with higher in-
tensity statin dosing versus the combined ‘‘no therapy plus
low intensity’’ group (adjusted odds ratio 5 0.60) were sim-
ilar to the odds for the lower intensity group alone (adjusted
odds ratio 5 0.71), suggesting that it is a power issue. Al-
though this may be why we showed a 40% reduction in the
odds of post-CTS AF compared with the ARMYDA-3 study,
which showed a 61% reduction with atorvastatin 40 mg
(a high-intensity therapy), we cannot exclude the possibility
that our use of beta-blockers and amiodarone attenuated the
benefits in our study or that the results were due to chance
or population differences. The impact of dosing intensity
on results is clearly the most important area for future re-
search because most patients with coronary disease receive
statin therapy, but very few receive high-intensity therapy.26
Further research using randomized controlled trials will
clearly be needed to answer this.
Conclusions
In patients with appreciable prophylactic use of beta-
blockers and amiodarone, preoperative statin administration
may still be beneficial in reducing the incidence of AF after
CTS.
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